Preclinical validation of a potent γ-secretase modulator for Alzheimer’s disease prevention

A potent γ-secretase modulator (GSM) has been developed to circumvent problems associated with γ-secretase inhibitors (GSIs) and to potentially enable use in primary prevention of early-onset familial Alzheimer’s disease (EOFAD). Unlike GSIs, GSMs do not inhibit γ-secretase activity but rather allos...

Descripción completa

Detalles Bibliográficos
Autores principales: Rynearson, Kevin D., Ponnusamy, Moorthi, Prikhodko, Olga, Xie, Yuhuan, Zhang, Can, Nguyen, Phuong, Hug, Brenda, Sawa, Mariko, Becker, Ann, Spencer, Brian, Florio, Jazmin, Mante, Michael, Salehi, Bahar, Arias, Carlos, Galasko, Douglas, Head, Brian P., Johnson, Graham, Lin, Jiunn H., Duddy, Steven K., Rissman, Robert A., Mobley, William C., Thinakaran, Gopal, Tanzi, Rudolph E., Wagner, Steven L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931646/
https://www.ncbi.nlm.nih.gov/pubmed/33651103
http://dx.doi.org/10.1084/jem.20202560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931646/
https://www.ncbi.nlm.nih.gov/pubmed/33651103
http://dx.doi.org/10.1084/jem.20202560

Ejemplares similares